

REMARKS

The foregoing amendment to the specification is supported in Figure 2A as originally filed and does not introduce new matter.

The amendment to Figure 2A merely adds a sequence identifier to the figure to comply with 37 C.F.R. 1.821(d) and does not introduce new matter.

Enclosed is a marked-up version of the changes made by this amendment. The enclosed pages are captioned "**VERSION WITH MARKINGS TO SHOW CHANGES MADE**"

Entry of the foregoing amendment is respectfully requested and favorable action on the merits is earnestly solicited.

Date: December 4, 2002

Respectfully submitted,




Jane K. Babin, Reg. No. 47,224

DELTAGEN, INC.
740 Bay Road
Redwood City, CA 94063
(650) 569-5100

CERTIFICATE OF MAILING UNDER 37 CFR 1.8

I hereby certify that this correspondence and its listed enclosures is being deposited with the United States Postal Service as First Class Mail, postage paid, in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on **December 4, 2002**
Name: **Deborah A. Mojarro**

Signed: _____



Date: _____

12/4/02

VERSION WITH MARKINGS TO SHOW CHANGES MADE

Page 9, lines 24-27 have been amended as follows:

Figure 2 (Panels A and B) shows design of the targeting construct used to disrupt melanocortin-3 receptor genes. Figure 2 (Panel A), which illustrates the target sequence (SEQ ID NO:1) for the targeting construct, shows the location and extent of the disrupted portion of the melanocortin-3 receptor genes, as well as the nucleotide sequences flanking the Neo^r insert in the targeting construct. Figure 2 (Panel B) shows the sequences identified as SEQ ID NO:3 and SEQ ID NO:4, which were used as the targeting arms (homologous sequences) in the melanocortin-3 receptor targeting construct.